Trino Therapeutics Ltd. is developing a novel class of anti-inflammatory compounds that, if data from preclinical models of ulcerative colitis bear out, could promote mucosal healing as effectively as standard steroid therapy while being safe enough for chronic use.

Trino's technology emerged from the work of Helen Sheridan, a medicinal chemist and associate professor at Trinity College Dublin, who derived the molecules from Pteridium aquilinum, a fern used in traditional Chinese herbal medicines for gastrointestinal conditions.